U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 25 results

Status:
US Approved Rx (2024)
First approved in 2024

Class (Stereo):
CHEMICAL (ABSOLUTE)



Vorasidenib (also known as AG 881) was developed as an isocitrate dehydrogenase (IDH) type 1 in the cytoplasm and type 2 in the mitochondria, with potential antineoplastic activity. It is known that IDH is an essential enzyme for cellular respiration...
Status:
US Approved Rx (1988)
First approved in 1988

Class (Stereo):
CHEMICAL (UNKNOWN)



Ioversol is an organoiodine compound that used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is indicated in adults for peripheral and coronary arteriography and left ventriculography, for exc...
Status:
US Approved Rx (1985)
First approved in 1985

Class (Stereo):
CHEMICAL (MIXED)



Iohexol is a nonionic, water-soluble radiographic contrast medium. Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not co...
Status:
US Approved Rx (2023)
First approved in 1985

Class (Stereo):
CHEMICAL (ABSOLUTE)



Iopamidol is a nonionic, low-osmolar iodinated contrast agent. Iopamidol is indicated for angiography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography, and adult and pediatric intravenous excretory...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Batabulin or T138067 (2-fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) covalently and selectively modifies the beta1, beta2, and beta4 isotypes of beta-tubulin at a conserved cysteine residue, thereby disrupting microtubule polymerization. C...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Temperocol is an investigative anti-cancer drug that inhibits the expression of survivin and CDK-1; discovered at Johns Hopkins University and under development by Erimos Pharmaceuticals. It has been tested in phase I/II clinical trials for Leukemia...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits a...
DMH1 is a potent and selective inhibitor of BMP signaling. DMH1 is a direct inhibitor of ALK2 BMP type-I receptor ALK2 (activin receptor like kinase-2). DMH1 potently inhibits neoplastic phenotype in cancer cells.
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

KU-60019 is a selective ATM kinase inhibitor. ATM is an ataxia telangiectasia (A-T) mutated, which plays a critical role in cell cycle checkpoints and DNA repair. Thus, specific small molecule inhibitors targeting ATM could perhaps be developed into ...
BAY-36-7620 is a potent and selective antagonist at mGlu1receptors and inhibits >60% of mGlu1a receptor constitutive activity (IC50 = 0.38 uM). BAY-36-7620 is thus the first described mGlu1 receptor inverse agonist. It impairs classical conditioni...